Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group

por von Tresckow, Julia, Heyl, Nikola, Robrecht, Sandra, Giza, Adam, Aldaoud, Ali, Schlag, Rudolf, Klausmann, Martine, Linde, Hartmut, Stein, Wolfgang, Schwarzer, Andreas, Fischer, Kirsten, Cramer, Paula, Eichhorst, Barbara, Hallek, Michael, Fink, Anna Maria
Publicado 2023

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BI...

por Yosifov, Deyan, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Jebaraj, Billy, Mertens, Daniel, Ritgen, Matthias, Schilhabel, Anke, Kreuzer, Karl-Anton, Maria Fink, Anna, Al-Sawaf, Othman, Langerbeins, Petra, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan, Cramer, Paula, Tausch, Eugen
Publicado 2023

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia

por Bloehdorn, Johannes, Braun, Andrejs, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E., Yeh, Ru-Fang, Klymenko, Tetyana, Tausch, Eugen, Eichhorst, Barbara, Bullinger, Lars, Fischer, Kirsten, Weisser, Martin, Robak, Tadeusz, Schneider, Christof, Gribben, John, Dahal, Lekh N., Carter, Mathew J., Elemento, Olivier, Landau, Dan A., Neuberg, Donna S., Cragg, Mark S., Benner, Axel, Hallek, Michael, Wu, Catherine J., Döhner, Hartmut, Stilgenbauer, Stephan, Mertens, Daniel
Publicado 2021